Navigation Links
Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Date:10/8/2009

an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellec
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today ... Heaton to the Board of Directors. QMC also announced formation ... , QMC Chief Science Officer and Board of Directors Member, along ... Rice University and Mr. Tomio Gotoh , a pioneer of ... " Quantum Materials welcomes two new outside Board members, ...
(Date:7/21/2014)... 21, 2014  Champions Oncology (OTC: CSBR), a company ... services to personalize the development and use of oncology ... operational results for the fourth quarter and fiscal year ... after market close. The company will host ... at 4:30 p.m. EDT (1:30 p.m. PDT). To participate ...
(Date:7/21/2014)... July 21, 2014 /PRNewswire-iReach/ -- Top Brooklyn Pediatrician ... responds to an article, which suggests that caffeine may ... Logo - http://photos.prnewswire.com/prnh/20140718/128611 A few ... coffee to children, but now it happens rather frequently, ... new study, published in the journal Pediatrics, discussed a ...
Breaking Medicine Technology:Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Dr. Michael Gabriel a Brooklyn Pediatrician Comments on an Article, Which Suggests Caffeine May Be Dangerous for Children 2
... 14 Spherix Incorporated,(Nasdaq: SPEX ) reported ... potential,type 2 diabetes drug, Naturlose(R), will expand outside ... of treatment-naive type II,diabetics are being considered. "This ... the first quarter of 2009, which is consistent ...
... a Safe and Effective ... Diabetes Patients, PHILADELPHIA, July 14 GlaxoSmithKline ... Drug Administration (FDA),updated the prescribing information for AVANDIA(R) ... Outcome Progression Trial,(ADOPT), a 4- to- 6 year ...
Cached Medicine Technology:Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S. 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 3
(Date:7/22/2014)... the University of Murcia have studied the changes ... a personality trait that causes difficulties in inhibiting ... and leads to unplanned actions without considering the ... indicator for predicting the risk of behavioural problems. ... the University of Murcia analyses whether the connectivity ...
(Date:7/22/2014)... CyraCom has been ranked as North ... translation and interpreting industry. Released June 2014 by the ... "The Language Services Market: 2014," also ranked CyraCom as ... up two spots from 2013. , In 2013, Common ... provide interpretation services – a subset of the language ...
(Date:7/22/2014)... 2014 The Muscular Dystrophy Association (MDA) and ... MUSCLE UP campaign that will raise funds to ... million Americans fighting muscle disease. , As part ... Jiffy Lube service centers through Sept. 1, 2014 to make ... make progress in the fight for muscle health. Since 2012, ...
(Date:7/22/2014)... The Restful Jaw Company announces its latest ... ®. The FDA-registered external device is clinically proven to ... fatigue and soreness during dental procedures. As such, patients ... do not need to take breaks or terminate procedures ... a vital solution in helping more than 31 million ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... drug already used to treat moderate-to-severe allergic asthma appears to ... helped by standard medications, new research suggests. The prescription ... hives, following U.S. Food and Drug Administration approval earlier this ... when Xolair is taken at a high dose for a ...
Breaking Medicine News(10 mins):Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3
... Indian Railways handed over the new five state-of-the-art coach ... train, to Impact India Foundation here today. Speaking on ... said that since 1991, Impact India Foundation with the ... of cost to nearly 4,50,000 persons in remote and ...
... McCartney is pregnant again, just 7 months after giving birth to ... expecting her third child with husband Alasdhair Willis before the end ... legend dad Sir Paul McCartney is thrilled after hearing the news. ... has been getting him through the tough times. He would be ...
... tobacco industrys deceptive practices have been aggressively quashed through ... Ibrahim , co-author of an analysis in the August ... ,In the article, Ibrahim tracks the rise and ... for the past 40 years. She chronicles industry strategies ...
... structure of a key molecule called 'P2X receptor' that ... might lead to the development of painkillers for recurring ... by a team of researchers including Dr Chris Thompson, ... University of Manchester. ,Researchers examined slime moulds, ...
... the capacity of short-term memory is a strong predictor of ... ,A study conducted by them has shown that an ... time, but people with high IQ levels can remember more ... Vogel of the university conducted laboratory experiments to test their ...
... without fear of prosecution in one English city's pubs ... national ban, the local council admitted Wednesday . ... can spark up knowing that bureaucrats cannot impose the ... to get enforcement powers in time for July 1, ...
Cached Medicine News:Health News:New Lifeline Express Train Inaugurated 2Health News:Tobacco Industry Promotes Antismoking Campaigns 2Health News:Tobacco Industry Promotes Antismoking Campaigns 3Health News:Blunder Leaves Smoking Ban Up in Smoke in Stoke 2
HME w/CO2 Sampling Port 22mm od/15mm od...
Indications For Usage: ,Infant (recommended tidal volume 20-70ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
Medicine Products: